Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVP-6124 phase 3 study in mild to moderate Alzheimer's disease
2013-002618-10Phase 3Terminated
- Sponsor
- FORUM Pharmaceuticals
- Start
- Dec 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of encenicline in Alzheimer's disease (AD) (3 arms), sponsored by FORUM Pharmaceuticals. Primary endpoints: Change from baseline to Day 182 in ADAS-Cog-13 and Change from baseline to Day 182 in DAD. Started Dec 2013; status: terminated.
02
Drugs
encenicline
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2013-002618-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002618-10.